This executive summary looks at how mid-size and emerging pharma companies can keep greater control of patient enrollment by treating site selection, timeline forecasting, and in-study adaptation as one connected process. Using an illustrative Phase 3 ALK-positive non–small cell lung cancer (NSCLC) trial and a representative five-study portfolio, it shows how the ZAIDYN clinical platform supports each decision with shared, evidence-based data.